Imaging and angiogenesis of malignant lymphoma with dynamic MRI, H-MRS, P-MRS and FDG-PET/CT for staging, mid treatment assessment and outcome.
- Conditions
- cancer of the lynphatic systemMalignant lymphoma10025322
- Registration Number
- NL-OMON35043
- Lead Sponsor
- niversitair Medisch Centrum Sint Radboud
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 30
• >= 18 years.
• WHO performance status: 0-3 (see appendix 1)
• Karnofsky score >= 80 (see appendix 2)
• Biopsy proven de novo or relapsed malignant lymphoma of any histological subtype. Relapsed patients who participated in this study during an earlier line of treatment may be re-entered in the study when fulfilling the inclusion criteria.
• Sufficient biopsy material present to perform anti-CD34 staining and subsequent MVD assessment.
• Other active malignancy (less than 5 years in complete remission) except skin carcinoma (non-melanoma).
• HIV positive patients.
• Patients with contra-indications for contrast enhanced MR exams:
o Claustrophobia,
o Cardiac pacemaker or pacemaker wiring in situ,
o Cerebral clips or metal artificial cardiac valves,
o Ossicle prosthesis
o Renal failure
• Pregnancy or breastfeeding .
• No staging FDG-PET/CT available.
• Inability of giving informed consent.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Correlation between DCE-MRI and MVD of malignant lymphoma tissue. Correlation<br /><br>between MRS and response to treatment. Correlation between MRS and<br /><br>vascularisation.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Evaluation of the correlation between FDG-PET/CT parameters, DCE-MRI parameters<br /><br>and the changes during treatment.</p><br>